CJC-1295 rebound effect: what happens when you stop

Last updated 2026-07-30

What is the "CJC-1295 rebound effect" people are describing?

The term shows up mostly in forums, not in journals. People use it to mean a fear that after you stop CJC-1295, your natural growth hormone output drops below whatever it was before you started, as if the pituitary got "lazy" from months of exogenous stimulation and needs time to recover, or worse, never fully recovers. That's a real physiological question worth asking about any hormone-adjacent peptide. But it's worth separating the question from the answer. Nobody has published a controlled human trial that measures GH secretion before, during, and after a CJC-1295 cycle specifically to test for a below-baseline rebound. The actual clinical literature on CJC-1295 is thin: a 2006 study in the Journal of Clinical Endocrinology & Metabolism looked at a modified GRF(1-29) with drug affinity complex (DAC) technology, the formal chemical description of what's now branded CJC-1295, and measured GH and IGF-1 responses to single and repeated dosing over weeks ^[1]. It did not run a long enough washout period or a large enough sample to answer the rebound question definitively. So when someone says "CJC-1295 rebound effect," they are usually describing a plausible mechanism, extrapolated from how other hormone axes behave, not a documented event in CJC-1295 users specifically. That distinction matters for anyone trying to decide how worried to be.

Does growth hormone drop below baseline after stopping CJC-1295?

There is no published clinical evidence in humans showing GH falls below pre-treatment baseline after stopping CJC-1295. What the existing data shows is a return toward baseline, not a rebound past it. In the 2006 Teichman et al. study, a single injection of the DAC-modified GRF(1-29) at doses of 30 mcg/kg to 60 mcg/kg produced a sustained increase in GH over roughly 6 days, and IGF-1 stayed elevated above baseline for about 9 to 11 days after a single dose ^[1]. With repeated dosing (weekly, for multiple weeks), IGF-1 levels stayed elevated throughout the dosing period without evidence of the pituitary going numb to it. The study describes "a sustained dose-dependent increase" in GH and IGF-1 and explicitly notes no evidence of GHRH receptor desensitization over the study period ^[1]. That's reassuring as far as it goes, but the study did not report GH secretion for weeks after stopping to see if it undershot the original baseline. So the honest answer is: the closest study we have found no desensitization during use and a normal-looking IGF-1 decay curve after stopping, but nobody ran the specific post-cessation rebound experiment people are worried about.

Why do people worry about pituitary desensitization at all?

The worry isn't invented from nothing. It comes from real endocrine principles that apply to other GHRH-axis interventions, then get applied to CJC-1295 by analogy. Natural GHRH is released from the hypothalamus in pulses, not as a steady drip. Continuous, non-pulsatile stimulation of G-protein coupled receptors, which is how the GHRH receptor works, can in some systems lead to receptor downregulation and reduced responsiveness over time. This is a documented phenomenon with continuous infusion of native GHRH in some animal and early human GHRH-analogue studies. It's also the reason some longer trials of GHRH analogues (like tesamorelin, which is FDA-approved for HIV-associated lipodystrophy) use daily injections rather than a constant infusion, to preserve the pulsatile signal the pituitary expects ^[2]. CJC-1295 with DAC is specifically designed to avoid a constant infusion problem in a different way: it binds albumin and releases slowly, giving a half-life of about 6 to 8 days in the Teichman study ^[1], rather than being a 24/7 IV drip. That's a meaningfully different exposure pattern than continuous infusion, but it is also not a natural pulse. Whether that particular exposure curve causes meaningful receptor downregulation over months of real-world use is something the short trials we have simply didn't run long enough to test.

CJC-1295 with DAC vs without DAC: does it change the rebound risk?

Yes, and this is the single most important distinction in the whole topic, because "CJC-1295" gets used loosely to describe two chemically different products with very different exposure profiles. CJC-1295 with DAC (drug affinity complex) is the modified GRF(1-29) that binds to albumin in the blood, extending its half-life to roughly 6 to 8 days based on the pharmacokinetic data in the 2006 study ^[1]. One injection keeps GH and IGF-1 elevated for days, which is why some protocols dose it once or twice a week. CJC-1295 without DAC is really just modified GRF(1-29), also called mod GRF 1-29 or sometimes confusingly labeled "CJC-1295 no DAC." It lacks the albumin-binding modification, so its half-life is short, on the order of 30 minutes, closer to native GHRH's clearance ^[3]. It's typically dosed multiple times a day to mimic pulsatile GHRH release, often alongside a ghrelin-mimetic like ipamorelin. | Feature | CJC-1295 with DAC | CJC-1295 no-DAC (mod GRF 1-29) |

How long does it take for GH and IGF-1 to return to baseline after stopping?

Based on the pharmacokinetic data available, IGF-1 elevation from a single dose of CJC-1295 with DAC persists for roughly 9 to 11 days before returning toward baseline, tracking the drug's slow clearance ^[1]. With repeated weekly dosing over several weeks, the washout period after the last dose would reasonably be expected to follow a similar multi-day to two-week pattern, though the published study didn't extend far enough past the dosing period to give an exact number for that scenario. For no-DAC CJC-1295 (mod GRF 1-29), the short half-life of about 30 minutes means any single-dose GH pulse resolves within hours, not days ^[3]. Repeated daily dosing over weeks to months hasn't been studied long-term for washout timing either. What's clear from the mechanism is that CJC-1295 with DAC's return-to-baseline timeline is set by pharmacokinetics (how long the drug physically stays in the blood), not by some separate "pituitary recovery period." There's no published evidence that the pituitary itself needs additional recovery time beyond the drug clearing out. That's a meaningfully different claim than "you need a rebound-avoidance protocol" language sometimes used in forum posts.

Is there any real evidence for a rebound crash, or is this bodybuilding forum lore?

This is worth saying plainly: the "rebound crash" as commonly described online, meaning GH dropping below your original baseline and staying suppressed, has no citation to a peer-reviewed human study on CJC-1295 that we could find. What does exist in the literature is evidence for the opposite concern with a related but different class of drugs: exogenous GH itself (not GHRH analogues) can suppress the body's own GH and IGF-1 axis through negative feedback, because high circulating GH and IGF-1 tell the hypothalamus and pituitary to slow down production. This is a documented mechanism in growth hormone deficiency and replacement literature generally, and it's part of why unsupervised exogenous HGH use carries real axis-suppression risk. CJC-1295 works upstream of that: it stimulates the pituitary to make more of its own GH rather than replacing GH directly, which is a mechanistically different risk profile, and the 2006 study found no evidence of pituitary exhaustion or blunted response across repeated weekly dosing ^[1]. The forum lore version of "rebound" often conflates these two mechanisms, treating a GHRH secretagogue like it carries the same suppression risk as injected GH. That conflation isn't supported by the mechanism or by the available dosing data, but it also hasn't been ruled out by a long enough trial to say with confidence it never happens in some subset of long-term users. Our CJC-1295 success rate page covers what the actual outcome data does and doesn't show, which is a useful companion to this mechanistic question.

Why is CJC-1295 usually paired with ipamorelin, and does that affect rebound?

CJC-1295 stimulates the GHRH receptor pathway. Ipamorelin is a ghrelin mimetic (a GH secretagogue that works through the ghrelin/GHS-R1a receptor), a separate pathway that also triggers pituitary GH release, with a strong reputation in early pharmacology work for being selective, meaning it doesn't meaningfully raise cortisol or prolactin the way older secretagogues did ^[4]. The rationale for combining them is that the two mechanisms are additive rather than redundant: GHRH analogues increase the amplitude of GH pulses, ghrelin mimetics increase the number and regularity of pulses, and using both together theoretically produces a larger GH response than either alone. This is a reasonable pharmacological argument, and it echoes older clinical research combining GHRH and GHRP-class compounds in GH-deficient patients. But it's important to say clearly: there is no large, published clinical trial specifically testing CJC-1295 plus ipamorelin as a combination for GH deficiency, muscle gain, fat loss, or any other outcome in humans. The pairing is common in off-label and research-chemical use, not something with its own dedicated approval or trial base. As for rebound specifically: adding ipamorelin doesn't change the CJC-1295 pharmacokinetics discussed above, and there's no evidence the combination causes a different or worse withdrawal pattern than CJC-1295 alone. If anything, the theoretical argument runs the other way, since ipamorelin's mechanism is separate from the GHRH receptor, so it wouldn't be expected to compound GHRH receptor downregulation even if that occurred. Anyone deciding on a stacked protocol should read the CJC-1295 results timeline to understand what a realistic multi-week course actually looks like before adding a second compound to the mix.

What does "pituitary desensitization" actually mean, and has it been shown with CJC-1295?

Desensitization means a receptor stops responding as strongly to the same stimulus over time, usually because the cell reduces the number of receptors on its surface or uncouples them from downstream signaling. It's a normal biological safety valve against overstimulation, seen across many hormone systems. For CJC-1295 specifically, the 2006 Teichman study is again the relevant data point: across multiple weekly doses over the study period, the authors reported sustained GH and IGF-1 elevation without a decline in response, describing the effect as maintained "without evidence of desensitization" over the dosing period studied ^[1]. That's a genuinely useful finding, but it covers weeks, not months or years. Real-world use in the peptide community often runs 8 to 16 week cycles or longer, well beyond what the published trial covered, so extrapolating "no desensitization" out to six months or a year of continuous use is an assumption, not a confirmed result. This is exactly the kind of gap where honest uncertainty matters more than reassurance. The mechanism looks favorable in the short term. Long-term human desensitization data for CJC-1295 specifically doesn't exist in the published record as far as we can find.

Should you cycle CJC-1295 to avoid a rebound, and is there evidence cycling helps?

Cycling (running the peptide for a set period, then stopping for a period before resuming) is common practice in the peptide-use community, often framed as 8 to 12 weeks on, followed by 4 to 8 weeks off. This practice is not derived from a published CJC-1295 desensitization trial; it's an inherited convention from anabolic steroid and SARMs culture, applied to peptides by analogy. There's nothing in the existing pharmacology data indicating that cycling on this schedule is necessary to preserve pituitary responsiveness, since the only real desensitization data available (the 2006 study) showed no loss of response across its dosing period without any cycling built in ^[1]. That doesn't mean cycling is harmful or pointless. Giving any hormone axis intermittent rest is a reasonable, low-risk, precautionary habit even without a study proving it's required, and it also gives you natural checkpoints to reassess whether the compound is doing anything worth continuing. For a broader framing on whether continuing at all is worth it, see is CJC-1295 worth it.

What are the real signs of GH axis suppression, and how would you actually know?

If you wanted to check whether your GH axis was suppressed below baseline after stopping CJC-1295, the only reliable way is a blood test, specifically IGF-1 (which is more stable day-to-day than GH itself, since GH is pulsatile and spikes unpredictably) ^[5]. Symptom-based self-assessment (feeling more tired, less recovered) is unreliable, because those symptoms have dozens of causes unrelated to GH. A clinically meaningful workup would involve an IGF-1 level drawn before starting, one drawn a few weeks after stopping (past the drug's washout window described above), and ideally a comparison to age- and sex-adjusted reference ranges, since IGF-1 naturally declines with age regardless of peptide use ^[5]. Nobody running informal peptide protocols is typically doing this kind of before/after lab work, which is part of why the rebound claim persists as anecdote rather than data: there's essentially no lab-verified case series showing a documented below-baseline IGF-1 after CJC-1295 discontinuation, for or against the rebound theory.

What does a provider-reviewed approach to this look like?

Given the gaps in long-term human data, the reasonable position isn't "rebound is definitely real" or "rebound is definitely a myth." It's that the mechanism is plausible in theory, unproven in practice for this specific compound, and worth monitoring with actual labs rather than guessing from how you feel. That's the kind of question worth raising with a prescriber who can order IGF-1 labs before and after a course, rather than relying on forum protocols for cycling schedules. CJC-1295 Co works with providers who review use cases individually and route fulfillment through a licensed compounding pharmacy partner, rather than unregulated research-chemical sellers, which matters given how much of the online CJC-1295 discussion mixes real pharmacology with unverified anecdote. If you're deciding whether to start at all, our CJC-1295 before and after and CJC-1295 reviews pages cover what documented and anecdotal users actually report, separate from the mechanism questions covered here.

Frequently asked questions

Does CJC-1295 cause a rebound effect where GH drops below baseline?

No published human study on CJC-1295 has documented GH or IGF-1 dropping below pre-treatment baseline after stopping. The 2006 pharmacokinetic study found sustained elevation during dosing with no evidence of desensitization, but it didn't track long-term post-cessation levels, so a below-baseline rebound remains unproven, not confirmed or ruled out.

How long after stopping CJC-1295 do hormone levels return to normal?

For CJC-1295 with DAC, IGF-1 stays elevated for roughly 9 to 11 days after a single dose based on published pharmacokinetics, tracking the drug's 6 to 8 day half-life. For no-DAC CJC-1295, with a roughly 30-minute half-life, GH effects resolve within hours. Neither form has published long-term washout data after months of use.

Is CJC-1295 with DAC more likely to cause pituitary desensitization than no-DAC?

It's theoretically more plausible, since DAC's sustained non-pulsatile exposure differs more from the body's natural GHRH pulses than the short-acting no-DAC version does. But no study has directly compared desensitization rates between the two forms in humans, so this remains a mechanistic argument, not a confirmed clinical finding.

What's the difference between CJC-1295 with DAC and without DAC?

DAC (drug affinity complex) is a chemical modification that lets CJC-1295 bind albumin in blood, extending its half-life to about 6 to 8 days, dosed once or twice weekly. No-DAC CJC-1295 (mod GRF 1-29) lacks that modification, clears in about 30 minutes, and is typically dosed multiple times daily.

Why is CJC-1295 combined with ipamorelin?

CJC-1295 works through the GHRH receptor pathway; ipamorelin works through the separate ghrelin receptor pathway. The rationale is that combining a GHRH analogue with a ghrelin mimetic produces a larger, more pulse-like GH release than either alone. No large published trial has tested this specific combination's clinical outcomes directly.

Can stopping CJC-1295 suddenly cause withdrawal symptoms?

There's no documented withdrawal syndrome for CJC-1295 in the published literature. Unlike drugs that cause physical dependence, GHRH analogues don't have a described acute withdrawal profile. Any symptoms after stopping are more plausibly explained by hormone levels gradually returning to baseline over days to weeks as the drug clears.

Does exogenous HGH cause rebound suppression, and is CJC-1295 the same?

Exogenous GH can suppress the body's natural GH/IGF-1 axis through negative feedback, a well-documented mechanism in GH replacement literature. CJC-1295 works upstream, prompting the pituitary to make its own GH rather than replacing it, which is a mechanistically different and generally lower suppression-risk profile, though not zero-risk by default.

How would I know if my GH axis was suppressed after using CJC-1295?

The only reliable method is a blood IGF-1 test, since GH itself is too pulsatile for a single measurement to be meaningful. Compare a baseline IGF-1 (before starting) to a level drawn a few weeks after stopping, past the drug's washout window, ideally interpreted against age-adjusted reference ranges by a provider.

Is cycling CJC-1295 necessary to prevent rebound or desensitization?

There's no published evidence that cycling is required to prevent desensitization; the only data available showed sustained response without cycling over its study period. Cycling is a low-risk precaution borrowed from steroid and SARM culture rather than a data-backed requirement specific to CJC-1295.

What does the actual research say about CJC-1295's effects on GH and IGF-1?

A 2006 study in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 (DAC-modified GRF 1-29) produced dose-dependent, sustained increases in GH and IGF-1, with IGF-1 elevated for 9 to 11 days after a single dose and no signs of desensitization across repeated weekly dosing during the study period.

Is the CJC-1295 rebound effect bodybuilding lore or real science?

It's largely forum-derived reasoning applied by analogy from receptor biology and other hormone axes, not a phenomenon directly documented in a CJC-1295 human trial. The underlying mechanism (receptor desensitization from sustained stimulation) is real in general endocrinology, but it hasn't been specifically confirmed or measured for CJC-1295 users after discontinuation.

Does no-DAC CJC-1295 avoid the rebound concern entirely?

It reduces the theoretical risk because its short half-life mimics pulsatile GHRH release more closely than the sustained DAC version. But "reduces theoretical risk" isn't the same as "proven safe from rebound." No long-term human study has tested either form specifically for post-cessation GH axis effects.

Sources

1. Journal of Clinical Endocrinology & Metabolism, Teichman et al. 2006: CJC-1295 (DAC-modified GRF 1-29) pharmacokinetics, half-life, and sustained GH/IGF-1 elevation without desensitization over the dosing period
2. FDA, Egrifta (tesamorelin) prescribing information: Tesamorelin, an FDA-approved GHRH analogue, is dosed as a daily injection to preserve pulsatile GH signaling
3. NCBI Bookshelf / StatPearls, Growth Hormone Releasing Hormone physiology: Native GHRH and short-acting GHRH fragments have short circulating half-lives, consistent with pulsatile signaling
4. NCBI PubMed, Raun et al. 1998, ipamorelin selectivity study: Ipamorelin is a selective GH secretagogue with minimal effect on cortisol and prolactin compared to older GHRPs
5. PubMed, Clemmons 2011, IGF-1 assay use in growth hormone disorders: IGF-1 is used as a stable marker of GH secretion because direct GH measurement is confounded by its pulsatile release pattern